Sugammadex versus neostigmine for reversal of neuromuscular blockade and postoperative pulmonary complications (SNaPP): an international, randomised, controlled, phase 4 trial

RECOMMENDED

Pulmonary Hypertension

Effect of riociguat on exercise following balloon pulmonary angioplasty in patients with inoperable chronic thromboembolic pulmonary hypertension in Japan (THERAPY-HYBRID-BPA): a multicentre, double-blind, randomised, controlled, phase 4 trial

★ 3 Recommended by Dr. med. Martin Frey, Faculty Member

★ 1 Recommended by Dr Marcus Hesse, Faculty Member

Lancet Respir Med

Shimokawahara H, Nishizaki M, Inami T, Kubota K, Taniguchi Y, Miyagi A, Kikuchi H, Goda A, Miyanaga S, Hashimoto H, Saito AM, Sekimizu M, Matsubara H

doi: 10.1016/S2213-2600(25)00127-4

Asthma

Budesonide-formoterol versus terbutaline reliever in adults with asthma using maintenance inhaled corticosteroids in New Zealand (INFORM ASTHMA): an open-label, parallel-group, randomised, controlled, phase 4 trial

Lancet Respir Med

Noble JH, Bean O, Perry M, Sayers R, Cullen R, Black B, Holliday M, Eathorne A, Shortt N, Kirton L, Perry B, Bruce P, Leung W, Pavord ID, Weatherall M, Beasley RW, INFORM ASTHMA collaborators

doi: 10.1016/S2213-2600(25)00327-3

COMMENTED

Respiratory Tract Infection

Dupilumab versus omalizumab in patients with chronic rhinosinusitis with nasal polyps and coexisting asthma (EVEREST): a multicentre, randomised, double-blind, head-to-head phase 4 trial

★ 3 Recommended by Dr. med. Martin Frey, Faculty Member

★ 3 Recommended and commented by Dr Marcus Hesse, Faculty Member

Lancet Respir Med

De Corso E, Canonica GW, Heffler E, Springer M, Grzegorzek T, Viana M, Horváth Z, Mullol J, Gevaert P, Michel J, Peters AT, Wagenmann M, Zaghloul S, Zhang M, Corbett M, Nash S, Angello JT, Radwan A, Deniz Y, Martin A, Hellings PW

doi: 10.1016/S2213-2600(25)00287-5

COMMENTED

COPD

Summary of Research: Ensifentrine, a Novel Phosphodiesterase 3 and 4 Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease: Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase III Trials (the ENHANCE Trials)

★ 2 Recommended by Dr. med. Martin Frey, Faculty Member

★ 2 Recommended and commented by Dr Marcus Hesse, Faculty Member

Adv Ther

Anzueto A, Barjaktarevic IZ, Siler TM, Rheault T, Rickard K, O'Donovan K, Sciurba F

doi: 10.1007/s12325-026-03514-6

Lung Cancer

Benmelstobart plus anlotinib versus pembrolizumab as first-line treatment for PD-L1-positive, advanced non-small-cell lung cancer (CAMPASS): a blinded, randomised, controlled, phase 3 trial

Lancet Oncol

Zhong H, Wang J, Yang R, Luo Y, Zuo W, Zhang W, Xie C, Li Q, Liu Q, Xu X, Wang Q, Yu Y, Chen Y, Yi T, Min X, Shi J, Yang J, Sun H, Chen H, Shi H, Gao J, Shi J, Zhang B, Chu T, Li K, Han B, CAMPASS Investigators

doi: 10.1016/S1470-2045(26)00049-5

Bronchi

Endotypes of Pseudomonas aeruginosa Infection in Bronchiectasis Are Associated with Inhaled Antibiotic Response: Results from Two Randomised, Double-Blind, Placebo-controlled, Phase III Trials (ORBIT 3 and ORBIT 4)

Am J Respir Crit Care Med

Hull RC, Stobo J, Abo-Leyah H, Richardson H, Alferes de Lima Headley D, Long MB, Hennayake C, Gilmour A, Johnson ED, Tunney M, Dicker AJ, Kewin E, Huang JTJ, Haworth CS, Chalmers JD

doi: 10.1164/rccm.202501-0159OC

Tuberculosis

Bedaquiline, delamanid, linezolid, and clofazimine for rifampicin-resistant and fluoroquinolone-resistant tuberculosis (endTB-Q): an open-label, multicentre, stratified, non-inferiority, randomised, controlled, phase 3 trial

Lancet Respir Med

Guglielmetti L, Khan U, Velásquez GE, Gouillou M, Ali MH, Amjad S, Kamal F, Abubakirov A, Ardizzoni E, Baudin E, Bektassov S, Berry C, Bonnet M, Chavan V, Coutisson S, Dakenova Z, de Jong BC, Dinh LV, Ferlazzo G, Kirakosyan O, Lachenal N, Lecca L, McIlleron H, Mikanda KK, Mucching-Toscano S, Mulders W, Mushtaque H, Nahid P, Nguyen DV, Nguyen NV, Oyewusi L, Motta I, Panda S, Patil S, Pham TH, Phan DT, Phan HTT, Phillips PPJ, Ruiz J, Rupasinghe P, Salahuddin N, Sanchez-Garavito E, Seung KJ, Asfaw MT, Vargas Vasquez D, Rich ML, Varaine F, Mitnick CD, endTB-Q Clinical Trial Team

doi: 10.1016/S2213-2600(25)00194-8

Lung Cancer

Aumolertinib with or without chemotherapy in EGFR-mutated advanced non-small-cell lung cancer (AENEAS2): an open-label, multicentre, randomised, controlled, phase 3 trial

Lancet Oncol

Li Z, Hu J, Chen J, Yu Y, Meng X, Dong X, Hu Y, Ji Y, Liu H, Wang W, Ning F, Zhang Z, Liu C, Zhang Z, Wang Q, Zheng W, Wang H, Qu X, Chen Z, Fan S, Zhang X, Lu S

doi: 10.1016/S1470-2045(26)00090-2

COPD

Safety and efficacy of astegolimab for COPD with frequent exacerbations regardless of baseline blood eosinophil counts (ALIENTO and ARNASA): randomised, double-blind, placebo-controlled, phase 2b and 3 trials

Lancet

Papi A, Greening NJ, Bhatt SP, Roche N, Celli B, Wedzicha JA, Agustí À, Tal-Singer R, Han MK, Janssens W, Hanania NA, Nair P, Bremner P, Porpodis K, Shibata Y, Korn S, Yang T, Gordon O, Saenz R, Ng J, Cheung DS, Devine J, Grimbaldeston MA, Zhang W, Yang X, Mohan D, Vogelmeier CF, Brightling CE, ALIENTO and ARNASA investigators

doi: 10.1016/S0140-6736(26)00637-9

Related content

Effect of riociguat on exercise following balloon pulmonary angioplasty in patients with inoperable chronic thromboembolic pulmonary hypertension in Japan (THERAPY-HYBRID-BPA): a multicentre, double-blind, randomised, controlled, phase 4 trial

Budesonide-formoterol versus terbutaline reliever in adults with asthma using maintenance inhaled corticosteroids in New Zealand (INFORM ASTHMA): an open-label, parallel-group, randomised, controlled, phase 4 trial

Dupilumab versus omalizumab in patients with chronic rhinosinusitis with nasal polyps and coexisting asthma (EVEREST): a multicentre, randomised, double-blind, head-to-head phase 4 trial

Summary of Research: Ensifentrine, a Novel Phosphodiesterase 3 and 4 Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease: Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase III Trials (the ENHANCE Trials)

Benmelstobart plus anlotinib versus pembrolizumab as first-line treatment for PD-L1-positive, advanced non-small-cell lung cancer (CAMPASS): a blinded, randomised, controlled, phase 3 trial

Endotypes of Pseudomonas aeruginosa Infection in Bronchiectasis Are Associated with Inhaled Antibiotic Response: Results from Two Randomised, Double-Blind, Placebo-controlled, Phase III Trials (ORBIT 3 and ORBIT 4)

Bedaquiline, delamanid, linezolid, and clofazimine for rifampicin-resistant and fluoroquinolone-resistant tuberculosis (endTB-Q): an open-label, multicentre, stratified, non-inferiority, randomised, controlled, phase 3 trial

Aumolertinib with or without chemotherapy in EGFR-mutated advanced non-small-cell lung cancer (AENEAS2): an open-label, multicentre, randomised, controlled, phase 3 trial

Safety and efficacy of astegolimab for COPD with frequent exacerbations regardless of baseline blood eosinophil counts (ALIENTO and ARNASA): randomised, double-blind, placebo-controlled, phase 2b and 3 trials